Topical antifungals in treatment of superficial cutaneous mycoses

Olga B. Tamrazova

For citation:

Abstract

Superficial cutaneous mycoses are a challenge for practical healthcare all over the world. Considering high incidence of cutaneous mycoses, it is obvious that there is a need to monitor the efficacy and safety of topical antifungals confirmed in the large-scale clinical trials. Today, drugs of two classes, allylamines and azoles, are considered to be the most effective antifungals for treatment of cutaneous mycoses. The review provides the analysis of the results of large-scale clinical trials and meta-analyses aimed to determine the role of modern topical antifungals in treatment of cutaneous mycoses. The options for optimization of the cutaneous mycosis treatment are exemplified by naftifine as a founder of the class of allylamines possessing not only antifungal, but also antibacterial and anti-inflammatory activity.
Keywords: cutaneous mycoses, dermatophytosis, onychomycosis, antifungal drugs, antifungals, naftifine.

References

1. Айзятулов Р.Ф. Грибковые заболевания кожи (лекции). Журнал дерматовенерологии и косметологии. 2001;(1):35-49.

Aizyatulov R.F. Fungal skin diseases (lectures). Journal of Dermatovenerology and Cosmetology. 2001;(1):35-49 (in Russian).

2. Сергеев А.Ю., Сергеев Ю.В. Грибковые инфекции: Руководство для врачей. М.: Бином-пресс, 2003.

Sergeev A.Yu., Sergeev Yu.V. Fungal infections: A guide for doctors. Moscow: Binom-press, 2003 (in Russian).

3. Borgers M, Degreef H, Cauwenbergh G. Fungal infections of the skin: infection process and antimycotic therapy. Curr Drug Targets 2005;6(8):849-62.

4. Charles AJ. Superficial cutaneous fungal infections in tropical countries. Dermatol Ther 2009;22(6):550-9.

5. Garber G. An overview of fungal infections. Drugs 2001;61(Suppl. 1):

1-12.

6. Потекаев Н.Н., Корсунская И.М., Серов Н.Д. Микотическая инфекция в России: заболеваемость, клинические характеристики, опыт терапии отечественными антимикотиками. Клиническая дерматология и венерология. 2006;(3):92-5.

Potekaev N.N., Korsunskaya I.M., Serov N.D. Mycotic infection in Russia: morbidity, clinical characteristics, experience of therapy with domestic antimycotics. Clinical dermatology and venereology. 2006;(3):92-5 (in Russian).

7. Иванова М.А., Огрызко Е.В., Бендриковская И.А. Динамика заболеваемости дерматомикозами в РФ в 2003–2007 гг. Клиническая дерматология и венерология. 2009;(2):26-31.

Ivanova M.A., Ogryzko E.V., Bendrikovskaya I.A. Dynamics of the incidence of dermatomycosis in the Russian Federation in 2003-2007. Clinical dermatology and venereology. 2009;(2):26-31 (in Russian).

8. Amorim AG, Schechtman RC, Azulay DR. Update on therapy for superficial mycoses: review. An Bras Dermatol 2013;88(5):764-74.

9. Walsh TJ, Rex JH. Fungal infections. Recent advances in diagnosis, treatment, and prevention of endemic and cutaneous mycoses. Infectious Disease Clinics 2003;17(Issue 1):1-12.

10. Vandeputte P, Ferrari S, Coste AT. Antifungal Resistance and New Strategies to Control Fungal Infections. Int J Microbiol 2012:2012:713687. DOI: 10.1155/2012/713687

11. Martins de Almeida LM, de Freitas Souza EA, Bianchin DB, Estivalet Svidzinski TI. In vitro response of cutaneous mycosis fungal agents to the most widely used systemic antifungals in dermatology. An Bras Dermatol 2009;84(3):249-55.

12. Саданов А.К., Березин В.Э., Треножникова Л.П. и др. Микозы человека и противогрибковые препараты. Монография. Алматы, 2016.

Sadanov A.K., Berezin V.E., Trenozhnikova L.P. et al. Human mycoses and antifungal drugs. Monograph. Almaty, 2016 (in Russian).

13. Соколова Т.В., Малярчук А.П., Малярчук Т.А. Результаты многоцентрового исследования по изучению встречаемости поверхностных микозов кожи в регионах Российской Федерации и оценке эффективности их лечения сертаконазолом. Клиническая дерматология и венерология. 2013;11(5):28-39.

Sokolova T.V., Malyarchuk A.P., Malyarchuk T.A. Results of a multicenter study on the occurrence of superficial skin mycoses in the regions of the Russian Federation and evaluation of the effectiveness of their treatment with sertaconazole. Clinical dermatology and venereology. 2013;11(5):28-39 (in Russian).

14. Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia 2008;166(5-6):353-67.

15. Meis JF, Verweij PE. Current management of fungal infections. Drugs 2001;61(Suppl. 1):13-25.

16. Касихина Е.И. Рациональный выбор топического антимикотика. Клиническая дерматология и венерология. 2015;(2):87-91.

Kasikhina E.I. Rational choice of topical antibiotic. Clinical dermatology and venereology. 2015;(2):87-91 (in Russian).

17. Матушевская Е.В., Свирщевская Е.В. Применение методов метаанализа эффективности антимикотических препаратов в лечении микозов кожи. Лечащий врач. 2016;(5):70-4.

Matushevskaya E.V., Svirshchevskaya E.V. Application of methods of meta-analysis of the effectiveness of antimycotic drugs in the treatment of skin mycoses. The attending physician. 2016;(5):70-4 (in Russian).

18. Havlickova A, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses 2008;51(4):2-15.

19. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. The Cochrane Collaboration. 2007;(3):123. CD001434.

20. Rotta I, Otuki MF, Sanches AC, Correr CJ. Efficacy of topical antifungal drugs in different dermatomycoses: a systematic review with meta-analysis. Rev Assoc Med Bras (1992). 2012;58(3):308-18. English, Portuguese. PMID: 22735222.

21. Gupta AK, Einarson TR, Summerbell RC, Shear NH. An overview of topical antifungal therapy in dermatomycoses. A North American perspective. Drugs 1998;55(5):645-74.

22. Rotta I, Ziegelmann PK, Otuki MF et al. Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison metaanalysis involving 14 treatments. JAMA Dermatol 2013;149(3):341-9.

23. van Zuuren EJ, Fedorowicz Z, El-Gohary M. Evidence based topical treatments for tinea cruris and tinea corporis: a summary of a Cochrane systematic review. Br J Dermatol. 2014 Oct 7. DOI: 10.1111/bjd.13441

24. Stein Gold LF, Vlahovic T, Verma A et al. Naftifine Hydrochloride Gel 2%: An Effective Topical Treatment for Moccasin-Type Tinea Pedis. J Drugs Dermatol 2015;14(10):1138-44.

25. Vlahovic TC. The Role of Naftifine HCl 2% Gel and Cream in Treating Moccasin Tinea Pedis. J Drugs Dermatol 2016;15(2):s56-59.

26. Verma A, Olayinka B, Fleischer ABJr. An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of Naftifine HCl Gel 2% in Pediatric Subjects With Tinea Pedis. J Drugs Dermatol 2015;14(7): 686-91.

27. Kircik LH, Onumah N. Use of naftifine hydrochloride 2% cream and 39% urea cream in the treatment of tinea pedis complicated by hyperkeratosis. J Drugs Dermatol 2014;13(2):162-5.

28. Котрехова Л.П., Разнатовский К.И., Вашкевич А.А. Особенности течения микозов кожи на современном этапе и их рациональная терапия. Consilium Medicum. Дерматология. 2014;(1):31-4.

Kotrekhova L.P., Raznatovsky K.I., Vashkevich A.A. Features of the course of skin mycoses at the present stage and their rational therapy. Consilium Medicum. Dermatology. 2014;(1):31-4 (in Russian).

29. Stein Gold LF, Parish LC, Vlahovic T et al. Efficacy and safety of naftifine HCl Gel 2% in the treatment of interdigital and Moccasin type tinea pedis: pooled results from two multicenter, randomized, double-blind, vehiclecontrolled trials. J Drugs Dermatol 2013;12(8):911-8.

30. Parish LC, Parish JL, Routh HB et al. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. J Drugs Dermatol 2011;10(11):1282-8.

31. Parish LC, Parish JL, Routh HB et al. A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris. J Drugs Dermatol 2011;10(10):1142-7.

32. Сергеев А.Ю., Иванов О.Л., Сергеев Ю.В. Исследование современной эпидемиологии онихомикоза. Вестник дерматологии и венерологии. 2002;(3):31-5.

Sergeev A.Yu., Ivanov O.L., Sergeev Yu.V. A study of the modern epidemiology of onychomycosis. Bulletin of Dermatology and Venereology. 2002;(3):31-5 (in Russian).

33. Evans EG, James IG, Seaman RA, Richardson MD. Does naftifine have antiinflammatory properties? A double-blind comparative study with 1% clotrimazole/1% hydrocortisone in clinically diagnosed fungal infection of the skin. Br J Dermatol 1993;129(4):437-42.

34. Irvine CA, Kenilworth NJ. Naftifine cream 1% versus clotrimazole cream 1% in the treatment of tinea pedis Naftifine Podiatric Study Group. J Am Podiatr Med Assoc 1990;80(6):314-8.

35. Smith EB, Wiss K, Hanifin JM et al. Comparison of once and twice-daily naftifine cream regimens with twicedaily clotrimazole in the treatment of tinea pedis J Am Acad Dermatol 1990;22(6):1116-7.

36. Georgopoulos A, Petranyi G, Mieth H et al. In vitro activity of naftifine, a new antifungal agent. Antimicrob Agents Chemother 1981;19(3):386-9.

37 Favre B, Ryder NS. Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother 1996;40(2):443-7.

38. Birnbaum JE. Pharmacology of the allylamines. JAAD 1990;23(4):782-5.

39. Mühlbacher JM. Naftifine: a topical allylamine antifungal agent. Clin Dermatol 1992;(9):479-85.

40. Plaum S, Verma A, Fleischer ABJr e al. Detection and relevance of naftifine hydrochloride in the stratum corneum up to four weeks following the last application of naftifine cream and gel, 2%. J Drugs Dermatol 2013;12(9):1004-8.

41. Verma A et al. Naftifine demonstrates potent fungicidal activity against the most common dermatophyte species with no evidence of resistance. J Am Acad Dermatol 2012;(4):AB119.

42. Ghannoum M, Isham N, Verma A et al. In vitro antifungal activity of naftifine hydrochloride against dermatophytes. Antimicrob Agents Chemother 2013;57(9):4369-72.

43. Lecha M, Effendy I, Feuilhade de Chauvin M et al. Taskforce on onychomycosis education. Treatment options-development of consensus guidelines. J Eur Acad Dermatol Venereol 2005;19(Suppl. 1):25-33.

44. Choi TS, Solomon B, Nowakowski M et al. Effect of naftifine on neutrophil adhesion. Skin Pharmacol 1996;(9):190-6.

45. Tronnier H. Inflammatory dermatomycoses – comparative study of naftifine and a combination of a corticosteroid and an imidazole derivative. Mykosen 1987;30(1):98-103.

46. Monk JP, Brogden RN. Naftifine. A review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs 1991;(4):659-72.

47. Котрехова Л.П. Нафтифина гидрохлорид в терапии микоза стоп, осложненного бактериальной инфекцией и протекающего с выраженной воспалительной реакцией. Вестник дерматологии и венерологии. 2015;(3):3-8.

Kotrekhova L.P. Naphthyphine hydrochloride in the treatment of mycosis of the feet, complicated by bacterial infection and occurring with a pronounced inflammatory reaction. Bulletin of Dermatology and Venereology. 2015;(3):3-8 (in Russian).

48. Лыкова С.Г., Спицына А.В., Петренко О.С. Местная антимикотическая терапия: подробные ответы на актуальные вопросы. Русский медицинский журнал. 2015;(9):486.

Lykova S.G., Spitsyna A.V., Petrenko O.S. Local antimycotic therapy: detailed answers to topical questions. Russian Medical Journal. 2015;(9):486 (in Russian).

49. Тамразова О.Б. Возможности преодоления антибиотикорезистентности в терапии пиодермий. Клиническая дерматология и венерология. 2014;12(6):64-73.

Tamrazova O.B. The possibilities of overcoming antibiotic resistance in the treatment of pyoderma. Clinical dermatology and venereology. 2014;12(6):64-73 (in Russian).

50. Jing Sun, Yuxiang Zhang, Jianqiang Su et al. Naftifine enhances photodynamic therapy against Staphylococcus aureus by inhibiting staphyloxanthin expression. Dyes and Pigments 2020;179:108392. DOI: 10.1016/j.dyepig.2020.108392

51. Gupta AK, Ryder JE, Cooper EA. Naftifine: a review. J Cutan Med Surg 2008;12(2):51-8. DOI: 10.2310/7750.2008.06009. PMID: 18346400.

52. Millikan LE, Galen WK, Gewirtzman GB et al. Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis. J Am Acad Dermatol 1988;18(1 Pt. 1):52-6.

53. Effendy I, Friederich HC. Double-blind, randomized comparative study of naftifine solution (once daily) and clotrimazole solution (twice daily) in the treatment of dermatomycoses. Mykosen 1987;30(Suppl 1):

104-11.

54. Hira SK, Abraham MS, Mwinga A et al. Naftifine solution (1%) in the treatment of pityriasis versicolor in Zambia. Mykosen 1986;29(8):

378-81.

55. Naftin (naftifine hydrochloride) 1% cream product information. Merz Pharmaceuticals physicians’ desk reference. Vol 57. Montvale (NJ): Thomson PDR; 2003. p. 2132-3.

For citation:Tamrazova O.B. Topical antifungals in treatment of superficial cutaneous mycoses. Clinical review for general practice. 2024; 5 (6): 82–88 (In Russ.). DOI: 10.47407/kr2024.5.6.00439

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice